Could the Microbiota Be a Predictive Factor for the Clinical Response to Probiotic Supplementation in IBS-D? A Cohort Study.
diarrhoea
intestinal permeability
irritable bowel syndrome
microbiota
probiotics
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
20 Jan 2023
20 Jan 2023
Historique:
received:
14
11
2022
revised:
16
01
2023
accepted:
16
01
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Increasing evidence suggests the beneficial effects of probiotics in irritable bowel syndrome (IBS), but little is known about how they can impact the gut microbiota. Our objective was to evaluate the effects of a multistrain probiotic on IBS symptoms, gut permeability and gut microbiota in patients with diarrhoea-predominant IBS (IBS-D). Adults with IBS-D were enrolled in an open-label trial to receive a multistrain probiotic for 4 weeks. Abdominal pain, stool frequency, quality of life, gut permeability, and the luminal and adherent microbiota from colonic biopsies were evaluated before and after supplementation. Probiotics significantly improved symptoms and quality of life, despite having no impact on permeability in the global population. In the population stratified by the response, the diarrhoea responders displayed reduced colonic permeability after supplementation. The luminal and adherent microbiota were specifically altered depending on the patients' clinical responses regarding pain and diarrhoea. Interestingly, we identified a microbial signature in IBS-D patients that could predict a response or lack of response to supplementation. The multistrain probiotic improved the symptoms of IBS-D patients and induced distinct effects on the gut microbiota according to the patient's clinical response and initial microbiota composition. Our study further supports the need to develop individualised probiotic-based approaches regarding IBS.
Sections du résumé
BACKGROUND
BACKGROUND
Increasing evidence suggests the beneficial effects of probiotics in irritable bowel syndrome (IBS), but little is known about how they can impact the gut microbiota. Our objective was to evaluate the effects of a multistrain probiotic on IBS symptoms, gut permeability and gut microbiota in patients with diarrhoea-predominant IBS (IBS-D).
METHODS
METHODS
Adults with IBS-D were enrolled in an open-label trial to receive a multistrain probiotic for 4 weeks. Abdominal pain, stool frequency, quality of life, gut permeability, and the luminal and adherent microbiota from colonic biopsies were evaluated before and after supplementation.
RESULTS
RESULTS
Probiotics significantly improved symptoms and quality of life, despite having no impact on permeability in the global population. In the population stratified by the response, the diarrhoea responders displayed reduced colonic permeability after supplementation. The luminal and adherent microbiota were specifically altered depending on the patients' clinical responses regarding pain and diarrhoea. Interestingly, we identified a microbial signature in IBS-D patients that could predict a response or lack of response to supplementation.
CONCLUSIONS
CONCLUSIONS
The multistrain probiotic improved the symptoms of IBS-D patients and induced distinct effects on the gut microbiota according to the patient's clinical response and initial microbiota composition. Our study further supports the need to develop individualised probiotic-based approaches regarding IBS.
Identifiants
pubmed: 36838241
pii: microorganisms11020277
doi: 10.3390/microorganisms11020277
pmc: PMC9964083
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : PiLeJe Laboratoire
ID : no
Organisme : Région Pays de la Loire (MibioGate)
ID : no
Organisme : ANR Microbiautism
ID : ANR-19-CE14-0024
Références
Am J Physiol Gastrointest Liver Physiol. 2011 Nov;301(5):G799-807
pubmed: 21737778
Nutrients. 2021 Feb 26;13(3):
pubmed: 33652763
Nutrients. 2020 Jan 30;12(2):
pubmed: 32019158
BMC Gastroenterol. 2018 May 25;18(1):71
pubmed: 29801486
Therap Adv Gastroenterol. 2021 Feb 24;14:1756284821993586
pubmed: 33717210
Aliment Pharmacol Ther. 2014 Jul;40(1):51-62
pubmed: 24815298
Gastroenterology. 2017 Jan;152(1):111-123.e8
pubmed: 27725146
J Clin Gastroenterol. 2012 Oct;46 Suppl:S52-5
pubmed: 22955358
Gastroenterol Clin Biol. 1999 Jan;23(1):25-31
pubmed: 10219601
Benef Microbes. 2018 Feb 27;9(2):317-331
pubmed: 29488412
World J Gastroenterol. 2012 Aug 14;18(30):4012-8
pubmed: 22912552
World J Gastroenterol. 2014 Jun 14;20(22):6832-43
pubmed: 24944474
Gastroenterology. 2021 Jan;160(1):99-114.e3
pubmed: 32294476
Gastroenterology. 2019 Jul;157(1):97-108
pubmed: 30940523
Front Microbiol. 2019 Feb 05;10:90
pubmed: 30804899
Front Cell Infect Microbiol. 2022 Apr 01;12:859967
pubmed: 35433498
PLoS One. 2014 Jun 05;9(6):e99256
pubmed: 24901524
Clin Microbiol Rev. 2006 Jan;19(1):12-8
pubmed: 16418520
Dig Dis. 2022 Aug 25;:
pubmed: 36007493
Sci Rep. 2015 Aug 04;5:12693
pubmed: 26239401
Gastrointest Endosc. 2019 Mar;89(3):626-636
pubmed: 30120955
Gastroenterology. 2011 Nov;141(5):1792-801
pubmed: 21820992
Neurogastroenterol Motil. 2012 Jun;24(6):521-30, e248
pubmed: 22339879
Digestion. 2012;85(1):40-6
pubmed: 22179430
J Clin Med. 2020 Jul 23;9(8):
pubmed: 32717980
Genome Biol. 2014;15(12):550
pubmed: 25516281
Probiotics Antimicrob Proteins. 2011 Mar;3(1):1-7
pubmed: 22247743
Pain. 2009 Nov;146(1-2):41-6
pubmed: 19595511
EBioMedicine. 2021 Apr;66:103293
pubmed: 33813134
J Neurogastroenterol Motil. 2022 Oct 30;28(4):642-654
pubmed: 36250371
Front Cell Infect Microbiol. 2020 Sep 09;10:468
pubmed: 33014892
J Neurogastroenterol Motil. 2011 Jul;17(3):252-66
pubmed: 21860817
Intern Med. 2015;54(3):243-9
pubmed: 25748731
Biopsychosoc Med. 2012 Aug 03;6(1):16
pubmed: 22863114
Saudi J Gastroenterol. 2020 Mar-Apr;26(2):66-77
pubmed: 31898645
Front Pharmacol. 2020 Apr 03;11:332
pubmed: 32317962
Neurogastroenterol Motil. 2012 Mar;24(3):267-73, e110
pubmed: 22221410
Aliment Pharmacol Ther. 2013 Oct;38(8):864-86
pubmed: 23981066
Neurogastroenterol Motil. 2018 Dec;30(12):e13456
pubmed: 30136337
Front Pain Res (Lausanne). 2021 Sep 22;2:691689
pubmed: 35295488
Dig Liver Dis. 2017 Apr;49(4):331-337
pubmed: 28179092
Dig Dis Sci. 2017 Sep;62(9):2455-2463
pubmed: 28589238
J Clin Biochem Nutr. 2018 Mar;62(2):179-186
pubmed: 29610559
Nutrients. 2020 Apr 21;12(4):
pubmed: 32326347
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
Neurogastroenterol Motil. 2022 Sep;34(9):e14353
pubmed: 35302268
Scand J Gastroenterol. 2019 Jun;54(6):690-699
pubmed: 31190584
Aliment Pharmacol Ther. 2008 Oct 15;28(8):994-1002
pubmed: 18671775